Shanghai's innovative medicine opens the "chemotherapy-free" treatment for gastric cancer, the world's first gastric cancer perioperative immunotherapy single drug regimen has been implemented.

The world's first anti-PD-1 monoclonal antibody that achieves postoperative "chemo-free" treatment for gastric cancer has recently been approved in China--the innovative drug developed independently by Shanghai Fuhong Hanlin has become the only PD-1 inhibitor approved for the perioperative treatment of gastric cancer worldwide. Recently, Shanghai Fuhong Hanlin announced that the marketing authorization application for the anti-PD-1 monoclonal antibody H drug developed independently by the company has been officially approved by the National Medical Products Administration through the priority review procedure. It is used in combination with oxaliplatin and tegafur for neoadjuvant and postoperative monotherapy for gastric cancer that is operable with CPS5 of tumor PD-L1 expression. This innovative approach achieves postoperative treatment for gastric cancer using only immunotherapy without the need for chemotherapy, significantly reducing the toxic side effects of chemotherapy. While improving the accessibility of cure, it significantly improves the quality of life. Moreover, the innovative model of using immunotherapy instead of traditional adjuvant chemotherapy after surgery breaks the treatment barriers of long-term chemotherapy dependence in the perioperative period of gastric cancer, bringing new treatment options for patients with locally advanced gastric cancer and reshaping the clinical treatment landscape in this area. This approval by the NMPA makes H drug the world's first and only approved anti-PD-1 monoclonal antibody for the perioperative treatment of gastric cancer, filling the clinical treatment gap in this area, and marking an important breakthrough in the field of gastric cancer treatment in China.